Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With NVAF With a History of Stroke or Transient Ischemic Attack - a Nationwide Retrospective Observational Study Using Claims Data in Japan

NCT05321810 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05321810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05321810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With NVAF With a History of Stroke or Transient Ischemic Attack - a Nationwide Retrospective Observational Study Using Claims Data in Japan
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
April 15, 2022
Completion date
April 15, 2022
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-valvular atrial fibrillation